Danish Medicines Council rejects Novartis breast cancer drug

During its May meeting, the Danish Medicines Councils has rejected breast cancer drug Piqray, which is developed by Novartis, and has partly reversed a prior rejection of acute myeloid leukemia (AML) treatment Xospata, developed by Astellas Pharma.

Yesterday, Novartis suffered a blow in Denmark.

During its monthly meeting, members of the Danish Medicines Council gave a thumbs-down to the Basel-based firm, which had sought support from the council to use drug Piqray (alpelisib) as a combination treatment for certain patient groups with breast cancer.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs